[1] VOS T, ABRAHAM D F, MOHSEN N, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet, 2012, 380(9859):2163-2196.
[2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J].中国循环杂志, 2020, 35(9):833-854.
[3] DONG R, ZHANG M, HU Q Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy[J]. Int J Mol Med, 2018, 41(2):599-614.
[4] DUMIC J, DABELIC S, FLOGELl M. Galectin-3:an open-ended story[J].Biochim Biophys Acta, 2006, 1760(12):616-635.
[5] SHARMA U C, POKHAREL S, VAN BRAKEL T J, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J]. Circulation, 2004, 110(19):3121-3128.
[6] KIM H, LEE J, HYUN J W, et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues[J].Cell Biol Int, 2007, 31(2):655-662.
[7] VAN LINTHOUT S, TSCHOPE C. Inflammation - Cause or consequence of heart failure or both?[J].Curr Heart Fail Rep, 2017, 14(4):251-265.
[8] 吴刚, 周宇.左西孟旦对老年慢性心力衰竭心室重构及相关指标的影响[J].中华老年心脑血管病杂志, 2020, 22(4):393-396.
[9] 杨秀玲, 戴妍妍, 田桂芳, 等. 慢性心力衰竭病人血浆N端前体脑钠肽及半乳糖凝集素-3水平的变化及意义[J].实用老年医学, 2017, 31(7):678-680.
[10] SHARMA K, KASS D A. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies[J].Circ Res, 2014, 115(1):79-96.
[11] YU L, RUIFROK W P T, MEISSNER M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis[J].Circ Heart Fail, 2013, 6(1):107-117.
[12] SONG X, QIAN X Q, SHEN M, et al. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression[J]. Biochim Biophys Acta, 2015, 1853(2):513-521.
[13] VANDER VELDE A R, GULLESTAD L, UELAND T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure:data from CORONA and COACH[J].Circ Heart Fail, 2013, 6(2):219-226.
[14] IMRAN T F, SHIN H J, MATHENGE N, et al. Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population[J]. Am J Cardiol, 2017, 119(1):57-64.
[15] DE BOER R A, LOK DJ A, JAARSMA T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction[J]. Ann Med, 2011, 43(1):60-68.
[16] 江涛, 马晓, 董鹏飞, 等. 血清半乳糖凝集素3和脑钠肽及C反应蛋白与慢性心力衰竭急性发作失代偿患者30 d病死率的相关性[J].中华老年医学杂志, 2018, 37(1):19-23.
[17] LALA R I, LUNGEANU D, DARABANTIU D, et al. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure[J].Herz, 2018, 43(2):146-155.
[18] LI S, HAO X, ZHANG Y, et al. Perindopril and a galectin-3 inhibitor improve ischemic heart failure in rabbits by reducing Gal-3 expression and myocardial fibrosis[J]. Front Physiol, 2019, 10(3):267-275.
[19] CALVIER L, MARTINEZ-MARTINEZ E, MIANA M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries[J].JACC Heart Fail, 2015, 3(1):59-67.
[20] VERGARO G, PRUDHOMME M, FAZAL L, et al. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice[J].Hypertension, 2016, 67(13):606-612.
[21] CHALASANI N, ABDELMALEK M F, GARCIA-TSAO G, et al.Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension[J].Gastroenterology, 2020, 158(5):1334-1345. |
